Head-to-Head: which drug combo tames psoriatic arthritis better?
NCT ID NCT07398651
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two treatment combinations for adults with psoriatic arthritis who did not get enough relief from methotrexate alone. One group will receive apremilast plus methotrexate, the other adalimumab plus methotrexate. Researchers will measure joint and skin disease activity, as well as daily function, over the study period.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIATIC ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tanta University
Tanta, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new injection calm psoriatic arthritis?
- Can a once-daily pill tame psoriatic arthritis in everyday life?
- A single blood test may reveal whether a gene tied to transplant outcomes influences psoriatic arthritis risk.
- Can a 4-Minute chat rival a Dietitian's hour for heart health?
- Your plate may fight psoriatic arthritis: diet study tests food as medicine
- Real-World study tests whether aggressive early treatment improves psoriatic arthritis outcomes